Innovating
to meet real needs

We’re applying our expertise to innovate in the field of wellness and healthcare.

We are doing this through the development and commercialization of a pipeline of scalable products and brands, with the goal of supporting healthy lifestyles and addressing unmet needs.

Consumer wellness

We are passionate about finding new and better ways to improve lives by building healthier futures.

To succeed in this space, we’re taking a partnership approach. In tandem with our proprietary innovations and industry expertise, we’re teaming up with companies with existing sales and marketing capabilities to rapidly co-develop and co-commercialize each innovation.

“Our initial focus is on the ‘Purposeful Energy’ segment of the market, offering consumers healthier, holistic and engaging solutions to purposefully enhance their physical and mental energy levels.”
Kim Binderup
Kim Binderup
Chief Consumer Wellness Officer

Cannabinoids

We have an ambition to address unmet needs with best-in-class cannabinoid products and safe and effective delivery systems. We are doing this through Verdeya, a subsidiary of Aspeya.

Verdeya is pioneering a scientific and responsible approach to cannabinoids. With a patient and consumer-first mindset, it is developing and commercializing best-in-class medical and non-recreational cannabinoid products. Verdeya is doing this by combining scientific strength, world-class technical expertise, and data-driven insights.

Verdeya is committed to working with others to create consistent, high standards for cannabinoid quality, safety, and predictability.

To find out more, visit verdeyalife.com

“We believe that cannabinoids have a role to play in addressing health and wellbeing needs. But there is a need for science-backed products and standards for safety and quality.”
Julia Hoeng
Julia Hoeng
Vice President, Innovation & Product
Development (Cannabinoids)

ASY202

ASY202 is an orally inhaled formulation of dihydroergotamine (DHE) delivered via an easy–to–use, multidose inhaler, under investigation for the acute treatment of migraine.

ASY202 is not approved by any health authority for commercialization.

"Following the successful completion of our preclinical program and two Phase 1 clinical trials, we are conducting a randomized, double-blind, placebo-controlled crossover trial in adults to evaluate the efficacy, safety, and tolerability of a single dose of ASY202 for the acute treatment of migraine. In parallel, we are conducting a clinical trial in adults with asthma to evaluate pulmonary safety"
Dr Thomas Blaettler
Dr Thomas Blaettler
Chief Medical Officer
"Following the successful completion of our preclinical program and two Phase 1 clinical trials, we are conducting a randomized, double-blind, placebo-controlled crossover trial in adults to evaluate the efficacy, safety, and tolerability of a single dose of ASY202 for the acute treatment of migraine. In parallel, we are conducting a clinical trial in adults with asthma to evaluate pulmonary safety"
Dr Thomas Blaettler
Dr Thomas Blaettler
Chief Medical Officer

ASY202 is an investigational product and not approved by any health authority for commercialization in any territory

Find out more about ASY202